Chronic Refractory Cough Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Nerre Therapeutics, Avalo Therapeutics, Bellus Health, Genentech

Posted on
by

Chronic Refractory Cough Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Nerre Therapeutics, Avalo Therapeutics, Bellus Health, Genentech
The Chronic Refractory Cough Market size was valued USD 8,7845 Million in 2022 and the report offers an in-depth understanding of the Chronic Refractory Cough, historical and forecasted epidemiology as well as the Chronic Refractory Cough market trends in the 7MM.

DelveInsight’s “Chronic Refractory Cough Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Refractory Cough, historical and forecasted epidemiology as well as the Chronic Refractory Cough market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Chronic Refractory Cough market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Refractory Cough Market Forecast

 

Some of the key facts of the Chronic Refractory Cough Market Report: 

  • The Chronic Refractory Cough market size was valued USD 8,7845 Million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • According to DelveInsight, the number of prevalent cases of chronic constipation (CC) in the seven major markets (7MM) was estimated to be around 30,756,483 cases in 2022, with an anticipated rise expected by 2032 over the study period spanning from 2019 to 2032.

  • DelveInsight’s estimations indicate that within the seven major markets (7MM), the United States represented close to 42% of the prevalent population of chronic constipation cases, amounting to approximately 12,890,015 cases in 2022. This figure is projected to see further growth by 2032.

  • DelveInsight’s assessments reveal that the combined diagnosed prevalent cases of colorectal cancer (CRC) across the seven major markets (7MM) amounted to around 12,302,593 cases in 2022. Within the 7MM, the United States represented nearly 42% of these diagnosed prevalent cases of CRC in the same year.

  • In 2022, Germany reported the highest count of diagnosed prevalent cases of colorectal cancer (CRC) at 1,381,408, followed by Italy with 1,035,612 cases among the EU4 countries and the UK. Conversely, Spain had the lowest count of diagnosed prevalent cases of CRC among the EU4 countries and the UK during the same period.

  • The colorectal cancer (CRC) pipeline is in a state of flux and includes several promising candidates such as orvepitant maleate from Nerre Therapeutics, camlipixant from GSK, MK-7264 (gefapixant) from Merck, AX-8 from Axalbion, OFEV (nintedanib) from Boehringer Ingelheim, and NP-120 (ifenprodil) from Algernon Pharmaceuticals. Some of these treatments are anticipated to be introduced to the market between 2023 and 2032.

  • Key Chronic Refractory Cough Companies: Merck & Co, GSK, NeRRe Therapeutics, Trevi Therapeutics, Beijing Tide Pharmaceutical, Bellus Health Inc., Axalbion, Jiangsu Hansoh Pharma, Melius Pharma AB, Genentech, Inc., and others

  • Key Chronic Refractory Cough Therapies: MK-7264 (gefapixant), Camlipixant, Orvepitant Maleate, AX-8, Nalbuphine ER, TCR1672 tablet, BLU-5937, HS-10383, ME-015 (Suplatast Tosilate), GDC-6599, and others

  • The Chronic Refractory Cough epidemiology based on gender analyzed that it can be concluded that CRC is more common in women as compared to men

  • The Chronic Refractory Cough market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Refractory Cough pipeline products will significantly revolutionize the Chronic Refractory Cough market dynamics.

 

Chronic Refractory Cough Overview

A reflex action with some elements of intentional control is coughing. It is a component of the somatosensory system, which also includes visceral sensation, a reflexive motor response, and related behavioural reactions. Additionally, it can be acute (lasting less than three weeks), subacute (lasting between three and eight weeks), or chronic (lasting longer than eight weeks) in nature can be a sign of several common respiratory disorders.

 

Get a Free sample for the Chronic Refractory Cough Market Report 

https://www.delveinsight.com/report-store/chronic-refractory-cough-market

 

Chronic Refractory Cough Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Chronic Refractory Cough Epidemiology Segmentation:

The Chronic Refractory Cough market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Chronic Refractory Cough

  • Prevalent Cases of Chronic Refractory Cough by severity

  • Gender-specific Prevalence of Chronic Refractory Cough

  • Diagnosed Cases of Episodic and Chronic Chronic Refractory Cough

 

Download the report to understand which factors are driving Chronic Refractory Cough epidemiology trends @ Chronic Refractory Cough Epidemiology Forecast

 

Chronic Refractory Cough Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Refractory Cough market or expected to get launched during the study period. The analysis covers Chronic Refractory Cough market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Refractory Cough Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Chronic Refractory Cough Therapies and Key Companies

  • MK-7264 (gefapixant): Merck & Co

  • Camlipixant: GSK

  • Orvepitant Maleate: NeRRe Therapeutics

  • AX-8: Axalbion

  • Nalbuphine ER: Trevi Therapeutics

  • TCR1672 tablet: Beijing Tide Pharmaceutical

  • BLU-5937: Bellus Health Inc.

  • HS-10383: Jiangsu Hansoh Pharma

  • ME-015 (Suplatast Tosilate): Melius Pharma AB

  • GDC-6599: Genentech, Inc.

 

Discover more about therapies set to grab major Chronic Refractory Cough market share @ Chronic Refractory Cough Treatment Market

 

Chronic Refractory Cough Market Strengths

  • Growing research and development in the area may increase the probability of development of potential effective therapy for CRC. 

  • There is a significant increase in the prevalent population of CRC which will drive the market in the long run. 

 

Chronic Refractory Cough Market Opportunities

  • There is a lack of efficacious medication or therapy which provides an extensive market opportunity for the emerging companies to accelerate and dominate the CRC market.

  • Increased public awareness creates a lucrative opportunity for innovation of therapeutics to drive CRC market.

 

Scope of the Chronic Refractory Cough Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Chronic Refractory Cough Companies: Merck & Co, GSK, NeRRe Therapeutics, Trevi Therapeutics, Beijing Tide Pharmaceutical, Bellus Health Inc., Axalbion, Jiangsu Hansoh Pharma, Melius Pharma AB, Genentech, Inc., and others

  • Key Chronic Refractory Cough Therapies: MK-7264 (gefapixant), Camlipixant, Orvepitant Maleate, AX-8, Nalbuphine ER, TCR1672 tablet, BLU-5937, HS-10383, ME-015 (Suplatast Tosilate), GDC-6599, and others

  • Chronic Refractory Cough Therapeutic Assessment: Chronic Refractory Cough current marketed and Chronic Refractory Cough emerging therapies

  • Chronic Refractory Cough Market Dynamics: Chronic Refractory Cough market drivers and Chronic Refractory Cough market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Chronic Refractory Cough Unmet Needs, KOL’s views, Analyst’s views, Chronic Refractory Cough Market Access and Reimbursement 

 

To know more about Chronic Refractory Cough companies working in the treatment market, visit @ Chronic Refractory Cough Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Chronic Refractory Cough Market Report Introduction

2. Executive Summary for Chronic Refractory Cough

3. SWOT analysis of Chronic Refractory Cough

4. Chronic Refractory Cough Patient Share (%) Overview at a Glance

5. Chronic Refractory Cough Market Overview at a Glance

6. Chronic Refractory Cough Disease Background and Overview

7. Chronic Refractory Cough Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Refractory Cough 

9. Chronic Refractory Cough Current Treatment and Medical Practices

10. Chronic Refractory Cough Unmet Needs

11. Chronic Refractory Cough Emerging Therapies

12. Chronic Refractory Cough Market Outlook

13. Country-Wise Chronic Refractory Cough Market Analysis (2019–2032)

14. Chronic Refractory Cough Market Access and Reimbursement of Therapies

15. Chronic Refractory Cough Market Drivers

16. Chronic Refractory Cough Market Barriers

17.  Chronic Refractory Cough Appendix

18. Chronic Refractory Cough Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/